Sprache: Englisch
Verlag: Cambridge University Press, 2018
ISBN 10: 1107577306 ISBN 13: 9781107577305
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Sprache: Englisch
Verlag: Cambridge University Press, 2018
ISBN 10: 1107577306 ISBN 13: 9781107577305
Anbieter: Romtrade Corp., STERLING HEIGHTS, MI, USA
Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.
Sprache: Englisch
Verlag: Cambridge University Press, 2018
ISBN 10: 1107577306 ISBN 13: 9781107577305
Anbieter: Majestic Books, Hounslow, Vereinigtes Königreich
EUR 57,08
Anzahl: 1 verfügbar
In den WarenkorbZustand: Used.
Sprache: Englisch
Verlag: Cambridge University Press, 2018
ISBN 10: 1107577306 ISBN 13: 9781107577305
Anbieter: Ria Christie Collections, Uxbridge, Vereinigtes Königreich
EUR 59,35
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. In.
Anbieter: Revaluation Books, Exeter, Vereinigtes Königreich
EUR 77,53
Anzahl: 2 verfügbar
In den WarenkorbPaperback. Zustand: Brand New. 542 pages. 9.50x6.00x0.75 inches. In Stock.
Sprache: Englisch
Verlag: Cambridge University Press, 2018
ISBN 10: 1107577306 ISBN 13: 9781107577305
Anbieter: Kennys Bookstore, Olney, MD, USA
EUR 113,92
Anzahl: Mehr als 20 verfügbar
In den WarenkorbZustand: New. 2018. Paperback. . . . . . Books ship from the US and Ireland.
Sprache: Englisch
Verlag: Cambridge University Press, 2018
ISBN 10: 1107577306 ISBN 13: 9781107577305
Anbieter: AHA-BUCH GmbH, Einbeck, Deutschland
Taschenbuch. Zustand: Neu. Druck auf Anfrage Neuware - Printed after ordering - In this book, distinguished scholars Philip A. Rea, Mark V. Pauly, and Lawton R. Burns explore the science and management behind marketable biomedical innovations. They look at how the science actually played out through the interplay of personalities, the cultures within and between academic and corporate entities, and the significance of serendipity not as a mysterious phenomenon but one intrinsic to the successes and failures of the experimental approach. With newly aggregated data and case studies, they consider the fundamental economic underpinnings of investor-driven discovery management, not as an obstacle or deficiency as its critics would contend or as something beyond reproach as some of its proponents might claim, but as the only means by which scientists and managers can navigate the unknowable to discover new products and decide how to sell them so as to maximize the likelihood of establishing a sustainable pipeline for still more marketable biomedical innovations.